Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 250

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 250
---
 different from or in addition to (and may conflict with) those of other stockholders. Iris’s directors were aware of and considered these interests in evaluating the Business Combination and in recommending to stockholders that they approve the Business Combination. Stockholders should take these interests into account in deciding whether to approve the Business Combination. These interests include:

•

the fact that the Sponsor holds 6,900,000 Founder Shares and 4,177,778 Private Placement Warrants, which would expire worthless if a business combination is not consummated;

•

the fact that, unless Iris consummates the Business Combination, the Sponsor will not receive reimbursement for any out-of-pocket expenses incurred by an affiliate on behalf of Iris ($75,000 of such expenses were incurred that had not been reimbursed as of September 30, 2024) to the extent that such expenses exceed the amount of available proceeds not deposited in the Trust Account;

•

the fact that the Sponsor has made outstanding loans to Iris in the aggregate amount of approximately $1,453,720 as of September 30, 2024, which amount Iris will be unable to repay to the Sponsor to the extent that the amount of such loans exceeds the amount of available proceeds not deposited in the Trust Account if a business combination is not completed;

•

the fact that, if the Trust Account is liquidated, including in the event we are unable to complete an initial business combination within the required time period, the Sponsor has agreed to indemnify us to ensure that the proceeds in the Trust Account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the Trust Account on the liquidation date, by the claims of prospective target businesses with which we have entered into an acquisition agreement or claims of any third party for services rendered or products sold to us, but only if such a third party or target business has not executed a waiver of any and all rights to seek access to the Trust Account;

•

the fact that none of our officers or directors has received any cash compensation for services rendered to Iris, and all of the current members of the Iris Board are expected to continue to serve as directors at least through the date of the Special Meeting and may even continue to serve following the Business Combination and receive compensation thereafter;

•

the fact that the Sponsor and Iris’s officers and directors will lose their entire investment in Iris if the Business Combination or another qualifying business combination or an amendment the Iris Certificate of Incorporation by stockholder approval is not completed March 31, 2025